Analysts have turned bullish on Biocon’s strong performance for the fourth quarter ended March 2012. This has been the first strong performance of the company after eight consecutive weak quarters. Part of the reason for the strong growth is the weak base over the last eight quarters.

><table width='100%' border=0 cellspacing=0><tr><td style='FONT-FAMILY: Arial; FONT-SIZE: 18px; FONT-WEIGHT: bold; COLOR: #0253B7;'>Web view: Analysts upbeat on Biocon's Q4 numbers</td></tr><tr><tr><td style='FONT-FAMILY: Arial; FONT-SIZE: 11px; '>HSBC upgrades stock to 

Web view: Analysts upbeat on Biocon's Q4 numbers

HSBC upgrades stock to overweight with price target of Rs 270, Deutsche marginally hikes price target to Rs 220

Also Read

Maruti Suzuki net dips in FY12, but Q4 better than expected

Biocon beats estimates but net down 3%

Dividends, interest income drive ICICI Bank's profit up 31%

Axis Bank Q4 net up 25% on lower provisioning

Indiabulls Financial Services Q4 net up 24% at Rs 303 cr

Explore News